Core Viewpoint - Nokia has lowered its 2025 operating profit guidance due to adverse currency fluctuations and tariff impacts, adjusting the range from EUR 1.9 billion to EUR 2.4 billion down to EUR 1.6 billion to EUR 2.1 billion [2][8]. Financial Guidance Update - The updated comparable operating profit outlook for 2025 is now EUR 1.6 billion to EUR 2.1 billion, down from the previous range of EUR 1.9 billion to EUR 2.4 billion [4][8]. - The guidance for free cash flow conversion from comparable operating profit remains unchanged at 50% to 80% [4]. - The new guidance is based on a EUR:USD exchange rate of 1.17, compared to the previous rate of 1.04 used in January [2][4]. Impact of External Factors - Currency fluctuations, particularly the weaker USD, are expected to have a negative impact of approximately EUR 230 million on the operating profit, which includes EUR 140 million operationally and EUR 90 million from non-cash venture fund currency revaluations [3]. - The current tariff landscape is anticipated to further impact the full year operating profit by EUR 50 million to EUR 80 million [3]. Preliminary Financial Results - For the second quarter, Nokia expects to report net sales of approximately EUR 4.55 billion and a comparable operating profit of EUR 300 million, which includes a negative impact of EUR 50 million from its venture funds primarily related to currency [5][8]. - The official release of the second quarter and half-year 2025 financial results is scheduled for July 24, 2025 [5].

Core Points - Columbus A/S has adjusted its full-year financial guidance for 2025 due to a challenging macro-economic environment impacting customer decision-making on major IT projects, leading to project postponements and extended sales processes [1][2] - The revenue guidance has been revised from an expected organic growth of 7-9% to approximately the same level as 2024, which is DKK 1.7 billion [4] - The EBITDA margin guidance has been adjusted from an expected range of 10-12% to a new expected range of 7-9% [4] Upcoming Events - Columbus will release its Interim Report for Q2 2025 on August 21, 2025, providing further details on performance, and will host a teleconference for investors and analysts on the same day at 13:00 pm CET [3]

Core Insights - Ionis Pharmaceuticals reported a first-quarter EPS loss of 93 cents, an improvement from a loss of 98 cents, and better than the consensus estimate of a $1.12 loss [1] - Revenue for the first quarter of 2025 increased by 10% to $132 million, surpassing the consensus of $125.32 million, driven by higher commercial revenue [1] Financial Guidance - The company raised its 2025 revenue guidance by over 20% to a range of $725-$750 million, compared to previous guidance of over $600 million and the consensus of $659.37 million [4] - Ionis expects a 2025 adjusted operating loss of less than $375 million, improved from prior guidance of less than $495 million, with cash and equivalents projected at approximately $1.9 billion [4] Product Performance - The drug Tryngolza (olezarsen) generated over $6 million in net product sales in its first full quarter post-approval in the U.S. [6] - Wainua (eplontersen) for polyneuropathy generated $39 million in sales, resulting in $9 million in royalty revenue for the first quarter of 2025 [6] - Spinraza (nusinersen) for spinal muscular atrophy achieved global sales of $424 million, leading to $48 million in royalty revenue in the first quarter of 2025 [6]